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Abstract
We live in an age of psychopharmacology.One in six persons currently takes
a psychotropic drug. These drugs have profoundly shaped our scientific and
cultural understanding of psychiatric disease. By way of a historical review,
we try to make sense of psychiatry’s dependency on psychiatric drugs in the
care of patients. Modern psychopharmacology began in 1950 with the syn-
thesis of chlorpromazine. Over the course of the next 50 years, the psychi-
atric understanding and treatment of mental illness radically changed. Psy-
chotropic drugs played a major part in these changes as state hospitals closed
and psychotherapy gave way to drug prescriptions. Our review suggests that
the success of psychopharmacology was not the consequence of increasingly
more effective drugs for discrete psychiatric diseases. Instead, a complex mix
of political economic realities, pharmaceutical marketing, basic science ad-
vances, and changes in the mental health-care system have led to our current
infatuation with psychopharmacology.
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1. INTRODUCTION
It was definitely a clinical depression and one that I was going to have to have help to overcome.What
I learned about it is your brain needs a certain amount of serotonin and when you run out of that, it’s
like running out of gas, it’s like you’re on empty. (Tipper Gore 1999, quoted in Hall 1999, p. A1)
The past 50 years could easily be characterized as the age of psychopharmacology. From a cul-
tural perspective, Prozac (fluoxetine; Eli Lilly and Company) has replaced Freud as shorthand for
talking about what ails us. From an economic perspective, we spend more money on psychotropic
drugs than on any other class of pharmaceuticals. From a clinical perspective, especially in the case
of psychiatry, psychiatrists have become much more comfortable writing a prescription for an an-
tidepressant than interpreting a patient’s unconscious motivations. From a scientific perspective,
psychotropic drugs have made possible fundamental insights into how the brain functions.
Knowing her words would appear in America’s most widely read national daily newspaper,
USA Today, Tipper Gore no doubt intentionally simplified her explanation for her depression
and how she fixed it. An advocate for better mental health care, Gore hoped her public confession
would encourage others to seek treatment.Unpacking her quotation, she believes that her sadness
was a disease like any other biological disease, rooted in biology with a specific pathophysiology.
Importantly, it is a pathophysiology that is explained by a deficiency of serotonin. As a “clinical
depression,” her biological explanation suffices as a complete-enough description. Any other de-
tails about her life and relationships are extraneous to her real problem, her serotonin-depleted
brain, which presupposes cure by a selective serotonin reuptake inhibitor (SSRI). Her explanation
for her depression expresses a commonsense truth that we now take for granted and that we use
26 Braslow • Marder
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simultaneously to explain as well as fix our distressed psyches. Our aim is to describe how this now
almost-too-obvious fact became fact. The story is more complicated than we might think.
Humans have used psychoactive substances since long before the advent of psychiatry, but the
modern history of psychopharmacology begins in 1950.We chronicle four different eras.The first,
the prehistory of modern psychopharmacology, spans from the mid-nineteenth century to 1950.
The second, the golden age of psychopharmacology, begins with the synthesis of chlorpromazine
in 1950 and ends in the mid-1960s. Researchers discovered all of our current psychotropic drug
classes in this moment of unrivaled productivity. Paradoxically, psychiatrists embraced these new
drugs with ambivalence, generally using them as adjuncts to what they saw as their more important
psychosocial and psychotherapeutic activities. Spanning from the mid-1960s to the late 1980s, the
third era marked startling and unprecedented changes for psychiatry, the science of the brain, the
fate of patients, and the commonsense vision of disease and therapeutics that we now take for
granted. Psychotropic drugs played a central part in these dizzying changes. Our fourth era, the
heyday of blockbuster antidepressants and antipsychotics, begins with the introduction of Prozac
in 1988 into the US market. Over 30 years, the new drugs promised to radically transform the
landscape of mental illness, but as the original patents expire, recent clinical trials have created
doubt about their unalloyed benefits.
2. PSYCHOPHARMACOLOGY BEFORE THERE WAS
PSYCHOPHARMACOLOGY: MID-NINETEENTH CENTURY TO 1950
Nineteenth-century asylum physicians were notorious for their liberal use of sedatives and hyp-
notics, including such drugs as bromides, chloral hydrate, hyoscine, paraldehyde, sulfonal, and
narcotics (Ackerknecht 1979). Physicians rarely claimed that these drugs actually treated mental
illness, rather they sedated, calmed, and soothed. Yet like physical restraint, according to most
practitioners, they hardly counted as treatment.
Occasionally, especially at its first introduction, one finds an enthusiastic report on the effects
of a particular sedative drug. For example, describing the effects of hyoscine,Drapes (1889, p. 942)
wrote: “It is incomparably superior to the older sedatives, such as morphine and chloral, and none
of the newer ones, in my opinion, approach it in value as a remedy for controlling paroxysms of
furious excitement and turbulent maniacal outbreaks.” Enthusiasm for hyoscine was short-lived.
The famous late-nineteenth-century British psychiatrist, Henry Maudsley (1895, p. 557) wrote
that “the reports of its successes, when examined, are mostly naive reports of its success, not in
curing but in ‘quieting the patient.’” For Maudsley, pharmaceutical agents, although useful, were
not curative: “Drugs can no more directly quell an insane delusion than they can eradicate an envy
or abate an ambition” (Maudsley 1895, p. 546). Raising concerns similar to those that would be
expressed about the new tranquilizing agents more than 50 years later, Maudsley cautioned:
Mechanical restraint, except under surgical necessities, was formerly abandoned…because it was
deemed better for the patient to let him have the relief and self-respect of pretty free exercise than
to keep him tied up like a mad dog…but it may be doubted whether its coarse bond did as much harm
as has been done by the finer means of chemical restraint which have been used to paralyse the brain
and render the patient quiet. (Maudsley 1895, pp. 554–55)
The barbiturates were among the first new psychotropic drug discoveries of the twentieth century.
Discovered by Emil Fischer and Joseph von Mering in 1903, barbiturate acid and its derivatives
proved simple and easy to administer and joined the nineteenth-century sedatives and hypnotics
as useful, although not terribly therapeutic, interventions.
www.annualreviews.org • History of Psychopharmacology 27
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3. CREATION OF MODERN PSYCHOPHARMACOLOGY: 1950–1964
The synthesis of chlorpromazine [marketed in the United States as Thorazine; Smith, Kline &
French (SKF)] in 1950 marks the beginning of modern psychopharmacology.Unlike the sedatives
and hypnotics, chlorpromazine was the first psychoactive agent that psychiatrists believed actu-
ally treated their patients’ mental ills instead of merely masking the underlying disease. Chlor-
promazine also inaugurated the most remarkable decade in the history of psychopharmacol-
ogy. During that decade, the pharmaceutical industry synthesized and marketed compounds that
came to define the future classes of psychotropic drugs. The list includes the antipsychotic drugs
(chlorpromazine), anxiolytic drugs (meprobamate in 1950, chlordiazepoxide in 1955),monoamine
oxidase inhibitor (MAOI) antidepressants (iproniazid in 1951), and the tricyclic antidepressants
(imipramine in 1951).
3.1. Discovery and Serendipity
Largely by luck, clinicians stumbled upon the psychotropic effects of these agents. Chlorpro-
mazine itself was the most famous case. Synthesized by Paul Charpentier of the French phar-
maceutical company Rhône-Poulenc, chlorpromazine was the culmination of a long process that
began in the mid-1800s with the production of synthetic dyes from coal tars. Organic chemist
August Bernthsen in 1883 identified and named the core structure, which he called a phenoth-
iazine nucleus, a structure seen both in dyes such asmethylene blue and in chlorpromazine (Kerner
& McCoy 2017).
In the 1930s and 1940s, researchers became increasingly interested in producing synthetic
antihistamines. This led Charpentier to modify and test for antihistaminic properties several phe-
nothiazine compounds.Promethazine was one of his early successes in 1947.Unlike contemporary
strict controls on testing new drugs, informal contacts with physicians were used by companies
to test newly synthesized compounds. In 1949, French military surgeon Henri Laborit tested a
small amount of promethazine as a preventative for shock and noted that it produced a “euphoric
quietude” in patients (Swazey 1974).
Charpentier continued working on further iterations of the phenothiazine nucleus, hoping to
generate even greater antihistaminic effects. On December 11, 1950, he synthesized R.P. 4560.
Rhône-Poulenc sent this new compound to several Paris physicians, including Laborit at the Val-
de-Grâce and psychiatrists Pierre Deniker and Jean Delay at the Centre Hospitalier Sainte-Anne.
Laborit was struck by the new compound’s ability to calm anxious patients without too much seda-
tion, and he encouraged a number of psychiatrist colleagues to try the new drug on their patients.
Deniker and Delay, meanwhile, reported in May 1952 on the ability of the drug to calm psychot-
ically agitated patients. That same year, the American pharmaceutical company SKF bought the
North American rights to chlorpromazine and receivedUS Food andDrug Administration (FDA)
approval to market it as Thorazine in May 1954.
Given the growing number of positive reports from France, SKF was fairly confident in the
drug’s psychiatric applications. In the advertisement introducing chlorpromazine to American psy-
chiatrists in theMay 1954 issue of theAmerican Journal of Psychiatry, SKF announced: “‘Thorazine’
is useful in controlling anxiety, tension, agitation, confusion, delirium, or hostility, whether oc-
curring in schizophrenic, manic-depressive, toxic, or functional states” (Farrar 1954). SKF also
marketed Thorazine for a variety of other ills, ranging from vomiting (its original FDA indica-
tion), nausea, and pruritus to hiccups. Rhône-Poulenc also recognized the many potential uses
of the new drug that it branded Largactil. (Swazey 1974, Grob 1994, Shorter 1997). SKF soon
realized that the psychiatric market was by far the most important. By 1956, four million pa-
tients in theUnited States had taken chlorpromazine—primarily for psychiatric reasons—yielding
28 Braslow • Marder
A
nn
u.
 R
ev
. C
lin
. P
sy
ch
ol
. 2
01
9.
15
:2
5-
50
. D
ow
nl
oa
de
d 
fro
m
 w
w
w
.an
nu
al
re
vi
ew
s.o
rg
 
A
cc
es
s p
ro
vi
de
d 
by
 U
ni
ve
rs
ity
 o
f C
al
ifo
rn
ia
 - 
Lo
s A
ng
el
es
 U
CL
A
 o
n 
05
/2
9/
19
. F
or
 p
er
so
na
l u
se
 o
nl
y.
 
CP15CH02_Braslow ARjats.cls April 12, 2019 13:51
$75 million in profits in 1955 alone (Overholser 1956, p. 198) and far exceeding SKF’s wildest ex-
pectations of returns on its $350,000 investment (Scull 2015). Over the next decade, Thorazine
sales drove the company’s rapid growth, from net sales of $53 million in 1953 to $347 million in
1970 (Scull 2015).
3.2. Market Expansion
Another drug with similar clinical properties to but very different origins from chlorpromazine
was introduced to North American psychiatry in 1954. It was derived from the plant Rauwolfia
serpentina, which been used in India for centuries for diverse ills including snake bites, fevers,
madness, and in the twentieth century, hypertension. Ciba isolated the active salt from the plant
in 1953 and named it reserpine; company pharmacologist Fredrick Yonkman tested the new com-
pound on animals and used the word tranquilizer to describe the effects. Leading American psy-
chiatrist Nathan S. Kline, interested in the psychiatric potential, convinced Ciba to undertake a
study at Rockland State Hospital in New York. In 1953, Kline tested the drug first on himself and
research staff, then on patients, and presented his results to the New York Academy of Sciences
the following year (Kline 1954). Reserpine was used extensively in the mid-to-late 1950s, but its
popularity waned due to its longer onset of action compared with chlorpromazine, propensity
to cause hypotension, and a growing number of reports that some patients become profoundly
depressed after taking it (Healy & Savage 1998).
The core reserpine molecule was not easily manipulated, but the phenothiazine core molecule
was, allowing pharmaceutical companies to create similarly acting compounds. By 1964, phar-
maceutical companies had synthesized, tested, and brought to market more than a dozen new
phenothiazines—for example, Sparine (promazine; AmericanHome Products),Vesprin (triflupro-
mazine; Bristol-Myers Squibb),Tentone (methoxypromazine; Lederle), Stelazine (trifluoperazine;
SKF), Prolixin (fluphenazine; Bristol-Myers Squibb), Mellaril (thioridazine; Sandoz), and Pacatal
(pecazine; Warner Chilcott)—but none achieved the fame and profits that Thorazine had gener-
ated for SKF.
3.3. Clinical Accounts
Psychiatrists did not routinely use the term antipsychotic until the late 1960s and 1970s. Instead,
reflecting the drugs’ clinical uses, psychiatrists used the terms major tranquilizers, ataractics, and
neuroleptics. The term major tranquilizer was employed quite early on to distinguish these drugs
from the minor tranquilizers such as meprobamate (see Section 3.4.3). A 1962 account made the
following comparison.
The Major Tranquilizers are characterized by the following points:
1. These drugs produce…emotional calmness with relatively little sedation; they have proved useful
in controlling the symptoms of acutely and chronically disturbed psychotic patients.
2. They are capable of producing the reversible extrapyramidal syndrome characterized by rigidity,
tremors, and drooling.
3. Annoying side reactions [are] relatively high with these drugs, and serious dangers do exist to some
extent.
4. They produce little, if any, dependency.
The Minor Tranquilizers are characterized by other points:
1. These drugs produce calmness or relaxation, but not of the same quality as that produced by the
major tranquilizers….They are useful in the treatment of psychoneurotic problems and common
nervous tension.
www.annualreviews.org • History of Psychopharmacology 29
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2. They do not produce extrapyramidal motor phenomena so characteristic of the major
tranquilizers.
3. Annoying side reactions with the use of these drugs is relatively low.Dangerous reactions are rare.
4. Habituation may occur. (Benson & Schiele 1962, pp. 5–7)
Delay and Deniker introduced the term neuroleptic in 1955 to emphasize the “extrapyramidal
motor phenomena” caused by themajor tranquilizers.Derived from theGreek, lepticmeans to take
hold or to seize, while neuro refers to the brain.Delay and Deniker believed that a crucial action of
chlorpromazine was to produce a state of “psychomotor indifference” that was especially effective
in quelling psychotic agitation and that the therapeutic calmwas produced by the samemechanism
that led to the extrapyramidal motor side effects (Healy 2002, p. 117). European psychiatrists used
the term neuroleptic more widely than Americans (López-Muñoz et al. 2005). Psychiatrists also
used the term ataractic, suggested by Laborit and derived from the Greek ataraxy—not disturbed,
calm—to describe chlorpromazine. Antipsychotic, the currently accepted term, first coined by
Heinz E. Lehmann in 1956 in an address to the Canadian Medical Association, did not achieve
widespread acceptance until the 1960s (Lehmann 1993, p. 300).
The range of terms reflects the varied biological effects of these new drugs.Willis Bower (1954)
at McLean Hospital conducted a trial of chlorpromazine in 1953 and published his findings in the
NewEngland Journal ofMedicine in 1954. In his open trial, he treated a total of 29 patients diagnosed
with the following disorders: manic psychoses, acute schizoaffective psychoses with manic fea-
tures, acute confusional schizophrenia, excited chronic schizophrenia, depressions, anxiety states,
and senile and arteriosclerotic psychoses. He found both good and poor results across all disease
categories. As in many early reports on phenothiazines, he expressed cautious, muted optimism:
“Chlorpromazine may have some effect on the agitation or excitement of chronic schizophrenia;
it appears to induce calm without changing mental content significantly….The drug does not ap-
pear to diminish hallucinosis” (Bower 1954, p. 692). In the first JAMA study on chlorpromazine,
WilliamWinkelman (1954) reported on 142 patients; he found it effective but not a replacement
for other therapies, especially psychotherapies.
Similarly, early reports in the American Journal of Psychiatry emphasized the broad range of
indications for chlorpromazine.
It may be applied to the treatment of all conditions in which vegetative disturbances play a role, such as
anxiety states, severe neurosis—including obsessions—symptoms following drug withdrawal, manic-
depressive disorders, certain cases of acute and florid schizophrenia, and in a wide variety of psychoso-
matic disorders. (Wortis 1954, p. 508)
Another author wrote that chlorpromazine had a place in “most types of mental disorder”
(Kinross-Wright 1954, p. 298).
Chlorpromazine was especially useful in quelling extreme forms of violence and agitation.
The patients were selected because they were difficult nursing problems….The symptomatology dis-
played by these patients was manifested by one or several of the following factors—extremely noisy
for prolonged periods of time, confusion of such a degree that they needed constant supervision, agi-
tated, destructive, hyperactive, impulsively assaultive, denudative, smearing, soiling, requiring repeated
seclusion and sedation. (Kurland 1955, p. 322)
“Agitated, destructive, hyperactive, impulsively assaultive, denudative, smearing, soiling” behav-
iors had led psychiatrists to give electroconvulsive therapy (ECT) and, if unsuccessful, lobotomy;
30 Braslow • Marder
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they quickly learned that phenothiazines were easier to prescribe and produced more reliable
outcomes, substantially diminishing the need for these drastic somatic treatments (Braslow 1997).
Lobotomy had spread throughoutWestern Europe andNorth America in the late 1940s as a treat-
ment of last resort for violent, extremely disturbed, and uncontrollable patients with psychoses.
Although chlorpromazine not infrequently produced a kind of apathy or indifference, similar to
that produced by lobotomy, it was the drug’s ability to replace the irreversible surgery that led to
its occasional description as a “chemical lobotomy” (Anton-Stephens 1954, Lehmann 1955).
The following case example, from a California state hospital patient record, illustrates why
chlorpromazine was so useful in the practical, everyday context of clinical care for individuals
for whom all previous interventions had failed. Admitted in 1942 and diagnosed with dementia
praecox, E.M. was in her late twenties, married and, on admission, was “delusional and confused.”
She continued to be psychotic and when she became increasingly aggressive, was given hundreds
of ECT treatments. When she remained unimproved, her doctors lobotomized her in 1948, but
with limited success. In a 1955 progress note, her physician wrote:
She remains unpredictable and aggressive and is quite uncooperative on the ward. A more radical type
of operation might be of benefit to the patient….Another method of possibly giving the patient high
doses of Thorazine might be equally successful. Prefrontal lobotomy denied.
Fortunately, E.M. improved sufficiently on chlorpromazine, avoiding the more radical lobotomy.
In fact, in California state hospitals, not a single lobotomy was performed after the introduction
of chlorpromazine (Braslow 1997).
3.4. Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, Minor
Tranquilizers, and Lithium
The antidepressants, MAOIs, minor tranquilizers, and lithium are each important in their own
right. Not only have they each played an important part in how we conceptualize and care for
individuals with mental illness, they also have had enormous significance for the pharmaceutical
industry and our broader cultural conceptions of mental distress. They, too, came into existence
during the same postwar period that gave birth to chlorpromazine; and their psychoactive prop-
erties were likewise discovered by good luck.
3.4.1. Tricyclic antidepressants. The tricyclic antidepressants are an excellent case in point.
Like numerous other pharmaceutical companies in 1955, Geigy scrambled to synthesize a drug to
compete with the spectacular success of chlorpromazine and gave one promising compound, an
iminodibenzyl, to Swiss psychiatrist Roland Kuhn to test. Kuhn tested the drug at the Münster-
lingen Cantonal Asylum and wrote to Geigy in August 1956 to emphasize that while it had none
of the tranquilizing and antipsychotic effects observed with chlorpromazine, the new compound
“has an obvious effect on depression. The vital depression visibly improves” (Shorter 2008, p. 60).
Nevertheless, Kuhn published his findings on imipramine (trade name Tofranil) in August 1957
(Healy 1997, p. 52).
Geigy launched the drug in 1957 in Switzerland. Kuhn’s first American publication on
imipramine appeared in 1958, summarizing his treatment of more than 500 patients with a va-
riety of diagnoses (Kuhn 1958). He concluded:
It was demonstrated that the compound has potent antidepressant action. Best responses were obtained
in cases of endogenous depression showing typical symptoms of mental and motor retardation, fatigue,
feeling of heaviness, hopelessness, guilt, and despair. (Kuhn 1958, p. 464)
www.annualreviews.org • History of Psychopharmacology 31
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Two points deserve emphasis. First,Kuhn’s careful clinical observations of imipramine’s antide-
pressant properties would have failed to meet any of our contemporary standards for clinical trials.
He had no control group; he utilized no rating scales; and he was not blinded to the treatment.
Yet he made a fundamental discovery although or, more likely, because he was unhindered by any
preconceptions that a more formal clinical trial might have imposed. As discussed in Section 4.2,
the introduction of the randomized controlled trial (RCT) into the evaluation of psychotropic
drugs was not simply the introduction of a neutral method. Instead, the RCT shaped the very
ways in which illness was (and is) conceptualized.
Second, imipramine (and, almost simultaneously, the MAOIs) helped to define a new disease
entity, namely depression. ECT and amphetamines helped to establish depressive states and neu-
rotic depression as treatable disorders (Rasmussen 2006). But the use of imipramine and, even
more so, amitriptyline emphasized the importance and prevalence of depression. The manufac-
turer of amitriptyline (trade name Elavil), Merck, asked a number of psychiatrists to evaluate its
possible antipsychotic properties in 1958. Frank Ayd thought that amitriptyline, given its molecu-
lar similarity to imipramine, probably had antidepressant properties. In 1960, he reported on the
outcome of 130 “office and hospitalized patients…whose predominant symptoms were: depressed
mood, psychomotor retardation, loss of interest, feelings of guilt, insomnia, anorexia, and func-
tional somatic complaints” (Ayd 1960, p. 320). In developing amitriptyline into an enormously
successful product, Merck helped sell depression as a treatable disease (Healy 1997). To help sell
depression, Merck bought and distributed 50,000 copies of Ayd’s 1961 book, Recognizing the De-
pressed Patient: With Essentials of Management and Treatment. Written for the general practitioner,
the book argues that depression is a ubiquitous disorder found not only in hospitals but also among
outpatients. The use of rating scales, notably the Hamilton Depression Rating Scale, which de-
fined depression using the same symptoms treated by imipramine and amitriptyline (Hamilton
1960), further instantiated depression as a real entity (although, as some have suggested, through
a tautology).
3.4.2. Monoamine oxidase inhibitors. Released as an antidepressant at the same time as
imipramine, iproniazid, the first MAOI, helped bolster the idea of depression as a nearly ubiq-
uitous illness that could be treated with psychopharmacological agents. Largely because of the
potential of MAOIs to precipitate a hypertensive crisis if one ingested food high in tyramine,
they never attained the same widespread popularity achieved by the tricyclics. However, as with
the previous drugs, researchers discovered the antidepressant properties of the MAOIs in a cir-
cuitous, serendipitous process. After WorldWar II, Hoffman–LaRoche obtained large supplies of
hydrazine,which had been used as a component of German rocket fuel.Using hydrazine, the com-
pany synthesized two drugs that they believed might have antituberculosis properties—isoniazid
(Rimifon) and iproniazid (Marsilid)—and launched both in 1951 (Shorter 2008).
In 1952, Irving J. Selikoff and Edward Robitzek (Selikoff & Robitzek 1952) published their
findings on the effectiveness of iproniazid and isoniazid in the treatment of tuberculosis. To
their surprise, iproniazid had the side effect of elevating patients’ mood. Five years later, Frank
Ayd and George Crane separately reported that depressed tuberculosis patients became less
depressed while on iproniazid. Nathan S. Kline was the first to report on iproniazid’s effects
on nontubercular depressed patients. Uncertain about the size of the market for drugs to treat
depression, Hoffman–La Roche almost withdrew support from Kline, but ultimately continued
support (López-Muñoz & Alamo 2009, p. 1567). By the end of the 1950s, three new MAOIs had
been introduced: isocarboxazid (trade name Marplan; Hoffman–LaRoche), phenelzine (trade
name Nardil; Warner Chilcott), and tranylcypromine (trade name Parnate; SKF).
32 Braslow • Marder
A
nn
u.
 R
ev
. C
lin
. P
sy
ch
ol
. 2
01
9.
15
:2
5-
50
. D
ow
nl
oa
de
d 
fro
m
 w
w
w
.an
nu
al
re
vi
ew
s.o
rg
 
A
cc
es
s p
ro
vi
de
d 
by
 U
ni
ve
rs
ity
 o
f C
al
ifo
rn
ia
 - 
Lo
s A
ng
el
es
 U
CL
A
 o
n 
05
/2
9/
19
. F
or
 p
er
so
na
l u
se
 o
nl
y.
 
CP15CH02_Braslow ARjats.cls April 12, 2019 13:51
3.4.3. Meprobamate and the benzodiazepines. The first genuine blockbuster psychiatric
drug in terms of sales, the minor tranquilizer meprobamate, was synthesized in 1951 and then
launched under the trade name Miltown in 1955. In 1946, working in Yorkshire, England, Frank
Berger began studying mephenesin and discovered during animal testing that it caused sedation.
Human testing showed that mephenesin also diminished anxiety and caused muscle relaxation.
In 1951, at Wallace Laboratories in the United States, Berger succeeded in developing a longer-
acting form of the compound (Shorter 2008). Four years later it was brought to market asMiltown
(Wallace Laboratories) and Equanil (under license toWyeth).Marketed for “anxiety, tension, and
mental stress,” sales of Miltown exceeded all expectations (Shorter 2008, p. 42). Since Wyeth had
the larger sales force, Equanil outsold Miltown by a factor of three to one by 1960 (Tone 2008,
pp. 72–73). Nevertheless, by 1965, more than 14 billion tablets of Miltown (amounting to about
500 million prescriptions) had been sold (Shorter 2008, p. 45).
Just as reports of meprobamate’s addictive properties surfaced, the first marketed benzodi-
azepine, chlordiazepoxide (Librium), appeared. Leo Sternbach at Hoffmann–LaRoche hoped to
create a novel new tranquilizer that would rival the success of Miltown, and, instead of modifying
the molecular structure of a known antianxiety drug, he began screening unique molecular enti-
ties. He started with benzheptoxdiazines, based on his previous experience with the compounds
and his belief that they might be biologically active, but he had no success in screening some 40
derivatives. One particular compound, labeled Ro 5-0690, was shelved when Sternbach was reas-
signed to work on antibiotics in 1956. In 1957, when cleaning up his lab, he sent the sample for
testing rather than throwing it out. Animal testing proved it was a potent muscle relaxant that
did not produce excessive sedation. In comparison to meprobamate, it was more potent, appar-
ently safer, and produced less sedation.Hoffman–LaRoche received FDA approval for Librium in
February 1960.
In synthesizing chlordiazepoxide, Sternbach inadvertently had created an entirely new class of
chemicals, the benzodiazepines. He and his group would go on to synthesize and patent a num-
ber of new benzodiazepines, including flurazepam (Dalmane) and clonazepam (Klonopin). His
most famous product, synthesized on October 26, 1959, was given the name diazepam (Valium).
Released in 1963, Valium redefined the meaning of blockbuster drug. It became the most widely
prescribed drug in the world between 1968 and 1981 and was the first drug in history to reach
sales of more than $100 million (Tone 2008, p. 153).
3.5. Psychopharmacology in Context
Often the theory and practice of psychodynamic psychiatry and psychopharmacology are por-
trayed as contradictory, mutually exclusive activities and allegiances. In the 1970s, psychiatrists
waged heated battles over the status of psychoanalytic knowledge, especially whether it would
have a role in the 1980 revised edition of the American Psychiatric Association’s Diagnostic and
Statistical Manual of Mental Disorders (DSM-III; Am. Psychiatr. Assoc. 1980). But, despite occa-
sional skirmishes, the 1950s illustrate a symbiotic relationship between psychodynamic psychiatry
and psychopharmacology. Paradoxically, although psychoanalysts had come to dominate the pro-
fession by the early 1950s, their influence on psychiatric science and practice contributed in no
small measure to the spectacular success of psychopharmacology. Two particular points are worth
noting this regard. First, largely driven by the psychoanalytic belief that there were no sharp divi-
sions between the normal and the pathological, psychiatrists substantially enlarged the domain
of the pathological, transforming many psychological ills that had previously been seen more
as problems of daily living into an orbit of psychiatric diseases treatable by clinical modalities
such as psychotropic drugs (Braslow & Starks 2005). Second, psychiatrists saw psychotropic drugs
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not as alternatives to psychotherapy but as critical adjuncts to treatment, making it easier for the
patient to participate in psychotherapy and the social world.
The changing epidemiology of patients in state hospitals illustrates the expanding domain of
the pathological. We see a marked expansion of the kinds and numbers of patients admitted into
state hospitals before and after World War II. Those admitted with nonpsychotic diagnoses in
California increased from 1% in 1935 to 17% in 1960. This increase was not simply a reshuffling
of diagnostic boundaries but, rather, a real expansion of legitimate objects of psychiatric treatment.
In California, these nonpsychotic disorders included psychoneurosis, psychopathic personality,
primary behavior disorders, sexual psychopathy, psychoneurotic reaction, personality pattern dis-
turbance, personality trait disturbance, antisocial reaction, special symptom reaction, and transient
situational personality disturbances (Starks & Braslow 2005).
The publication in 1952 of the first edition of the American Psychiatric Association’sDiagnostic
and Statistical Manual of Mental Disorders (DSM-I; Am.Psychiatr. Assoc. 1952) represented, in part,
the growing influence of psychodynamic psychiatry and the lingering influence of Adolf Meyer,
especially evident in the use of the word “reaction” to describe the major psychiatric diseases.
Meyer believed that psychiatric diseases were the product of (or a “reaction to”) a complex mix
of biological, social, and psychological factors, the latter reflecting the repression of unconscious
conflicts that, in turn, stemmed from complex past relationships and one’s innate predispositions.
The importance of the dimensional perspective in the 1950s is reflected in the formal adop-
tion of Eugen Bleuler’s “schizophrenia” over Emil Kraepelin’s “dementia praecox” in the DSM-I.
Kraepelin believed that psychiatric diseases represented real, discrete, and bounded disease entities
that were biologically rooted. In contrast, deeply influenced by psychoanalysis, Bleuler’s concep-
tion of schizophrenia better accommodated (rightly or wrongly) American psychiatrists’ growing
infatuation with psychoanalysis and its dimensional view of illness.
Bleuler, a Swiss psychiatrist, first coined the term schizophrenia in 1908 and in 1911 pub-
lished his most famous monograph,Dementia Praecox or the Group of Schizophrenias (Bleuler 1950).
American psychiatrists began using the term interchangeably with dementia praecox in the 1920s,
although Bleuler’s monograph did not appear in English until 1950. As American psychiatry was
increasingly influenced by psychoanalysis, schizophrenia became correspondingly a disorder with
amorphous boundaries, shaped as much by personal history, social relationships, and psychologi-
cal meaning as it was by biology. Thus, by reclassifying dementia praecox as “schizophrenic reac-
tion” in the 1952 DSM-I, the American Psychiatric Association acknowledged what had already
become fact, namely that even the most biological-appearing disease was a disorder that shaded
from nearly normal (e.g., latent and simple schizophrenic reactions) to the overtly psychotic (e.g.,
schizophrenic reaction, paranoid type). Such a view also meant that psychotherapy remained the
most effective intervention, with somatic treatments, drugs, and even ECT merely adjunctive to
the psychotherapeutic process (Sadowsky 2016).
3.6. Psychopharmacology in Everyday Clinical Practice
Although outpatient care grew rapidly after the war, state hospitals continued to be a crucial
part of American psychiatry well into the 1960s. The state hospital population peaked in 1955 at
about 550,000 resident patients. At the same time, conditions within these institutions improved
substantially as states, no longer constrained by thewar effort, invested large sums in staff and in in-
frastructure. Despite a common misconception that state hospital psychiatrists were uninterested
in their patients’ psychodynamics, they often employed psychoanalytic concepts in understanding
their patients. And they saw psychotropic drugs not as replacements for, but as important adjuncts
to, psychological and social treatments.
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We can see the influence of psychoanalytic thought clearly in the case of R. H., who was ad-
mitted to Stockton State Hospital in 1955. In his late teens he was diagnosed with schizophrenic
reaction. The physician’s diagnostic formulation placed the patient’s illness within a psychody-
namic framework. “The patient,” the psychiatrist summarized, “is a third generation of Italian
Catholic cultural heritage.”
The father appears to be very rigidly and aggressively domineering, and the mother appears to be a
warm and loving, but ineffectual, parent. There appears to be a great deal of conscious and unconscious
hostility between these parents….It is possible that the patient is torn between the desire to act out his
father’s hostility and the desire to be more positive or submissive like his mother.
Official Diagnosis: Schizophrenic reaction.
As this short summary suggests, the physician deemed the patient’s relationships with a “rigidly
and aggressively domineering” father and his “warm and loving, but ineffectual”mother as central
to making sense of the patient’s schizophrenic reaction. Further, when it came to therapeutic rec-
ommendations, the psychiatrist believed that psychotherapy was necessary to help make conscious
the unconscious conflicts that either led to or unmasked his psychotic illness. He also prescribed
Thorazine but, as he made clear, it was not treating the core of the illness. Six months after admis-
sion, the psychiatrist observed: “The patient appears to be responding to Thorazine, reducing his
agitated behavior. This is only an added effect. It is not affecting the components of his illness.”
Reflecting, as well as shaping, clinical practice, pharmaceutical companies encouraged psychi-
atrists to use psychotropic drugs (including antipsychotics) as adjuncts to psychotherapy. This is
illustrated (Figure 1) in an advertisement for Serpanray (reserpine, manufactured by Panray) that
appeared in the 1956 American Journal of Psychiatry. We see a distraught-looking man seated in a
desolate landscape. Just off to his side is a precipice. Behind him, a door is cracked slightly open
with a sliver of light shining through. On the other side of the door is a lush landscape with trees,
grass, and what appears to be a small town. The ad copy proclaims: “Opens the door to more
successful psychotherapy…Ataractic Therapy for Neuro-Psychiatric Conditions.”
From the beginning of the psychopharmacological revolution of the 1950s, psychiatrists held
a variety of views on the usefulness of psychotropic drugs in the context of psychotherapy. At one
extreme, some argued that psychotropic drugs completely interfered with psychotherapy. As one
psychiatrist put it in 1956: “With regard to the use of the drugs on acute patients with a great
deal of anxiety receiving psychotherapy, we have not used it because it allays the anxiety. The chap
then has no reason for continuing psychotherapy, and so won’t cooperate. Psychotherapy doesn’t
work with the drug” (Veterans Adm. 1956, p. 14). However, most claimed that psychotherapy and
psychotropic drugs worked together synergistically (Sarwer-Foner 1960). Few would have fore-
seen a future in which psychotropic drugs would either devalue the importance of psychotherapy
or, even more unimaginable, raise fundamental questions about the efficacy of psychotherapy.
4. FORGING DISEASE SPECIFICITY: 1964–1988
Between themid-1960s and the late 1980s, American psychiatry underwent radical changes. In the
1950s, it was a profession dominated intellectually by psychoanalysis and clinically bymassive state
hospital systems. Hardly 20 years later, both state hospitals and psychoanalysis had all but faded
away. The role of psychopharmacology in these changes is extremely complicated.We think these
larger, macro-level changes in the profession both were shaped by and shaped developments in
psychopharmacology. But we voice caution as to any causal assumptions in the story that follows.
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Figure 1
Serpanray advertisement from the American Journal of Psychiatry (Farrar 1956).
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Larger political, economic, and cultural forces no doubt had the biggest roles in shaping psychiatry
and psychopharmacology.
As clinical psychiatry moved out of state hospitals and psychoanalysis gave way to a more bi-
ologically informed psychiatry, psychopharmacology played a part in two major trends that oc-
curred between the mid-1960s and late 1980s. First, the discovery of psychotropic drugs in the
1950s had a central role in the explosive growth of the neurosciences. Second, psychiatry discov-
ered a new method for evaluating antipsychotics, namely the RCT. As we discuss below, the RCT
played a critical part in moving psychiatrists and other clinicians away from the dimensional way
of seeing disease to a more categorical vision of disease.We then look more closely at the ways in
which changes in clinical care were shaped by the psychopharmacological revolution.
4.1. Creating Neuroscience
Without toomuch exaggeration, the psychopharmacological discoveries were indispensable to the
creation ofmodern neuroscience and to our understanding of how neurons communicate with one
another. Prior to the 1950s, most scientists believed that central nervous system (CNS) neurons
communicated through electrical impulses. Neurochemical transmission had been recognized
since 1933, when Henry Dale definitively showed that acetylcholine was a chemical messenger
between synapses in the peripheral nervous system and at neuromuscular junctions, but its exact
mechanism remained obscure. From the mid-1950s onward, as researchers uncovered the central
role of chemical neurotransmitters in the CNS, psychopharmacological agents proved crucial. For
example, in the late 1950s and early 1960s, Arvid Carlsson proved the central role of dopamine in
the mechanism of action for phenothiazines, which become the basis for the dopamine hypothesis
of schizophrenia.
Another neurotransmitter was isolated in 1948 from platelets and named serotonin because
of its vasoconstriction properties and origins in serum. In 1952, Betty Twarog and John Welsh
identified serotonin as a neurotransmitter present in mammalian brains. In 1953, John Gaddum
discovered that LSD antagonized serotonin activity (Gaddum 1953).Given that LSD blocks sero-
tonin in the brain and given that LSD causes psychotic symptoms, it was logical to hypothesize
that serotonin is critical to sanity. In the same year, Dilworth Woolley and Elliott Shaw proposed
a serotonin model of schizophrenia based upon similar logic: “[T]he suppression of its [serotonin]
action results in mental disorder. In other words, it is the lack of serotonin which is the cause
of the disorder” (Baumeister & Francis 2002, p. 267). In 1955, Bernard Brodie and colleagues at
the US National Institute of Mental Health (NIMH) provided direct evidence for the physiolog-
ical function of serotonin and showed that reserpine depleted serotonin from neuronal storage
sites (Pletscher et al. 1955). In 1957, Carlsson and his colleagues further found that reserpine
depleted the catecholamines epinephrine, norepinephrine, and dopamine, as well as serotonin
(Carlsson 2001). They concluded that reserpine acted by nonspecifically blocking the storage of
all monoamines, which are depleted by subsequent metabolic breakdown (Baumeister & Francis
2002).
Carlsson then showed that they could reverse the motor effects of reserpine-treated mice
by giving the mice l-dopa, a metabolic precursor of dopamine but not of serotonin. This sug-
gested the importance of dopamine over serotonin; yet the role of dopamine in the CNS was
thought to be negligible (Carlsson et al. 1957). However, Carlsson and his colleagues suggested
that dopamine was more than a precursor to the other catecholamines. Carlsson then demon-
strated that dopamine mediated the effects of reserpine (Carlsson 2000). In a critical step to-
ward understanding how antipsychotic drugs in general might act, researchers in the early 1960s
demonstrated that dopamine was depleted in the autopsied brains of individuals with Parkinson’s
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disease and that the administration of l-dopa helped alleviate some of the motor symptoms of the
disease.
The fact that reserpine and the phenothiazine drugs produced Parkinsonian symptoms and
that there seemed to be a relationship between side effects and therapeutic efficacy strongly sug-
gested that dopamine was involved in the mechanism of action for antipsychotic drugs. Yet the
phenothiazines, similar to chlorpromazine, did not deplete dopamine storage. In 1963, Carlsson
andMargit Lindqvist performed experiments with chlorpromazine and haloperidol and suggested
that the drugs were blocking the catecholamine receptors rather than dopamine receptors specif-
ically. However, during the following decade, researchers were able to show that antipsychotic
drugs increased the concentration of dopamine brain metabolites, an effect directly proportional
to antipsychotic potency. By the mid-1970s, scientists definitively demonstrated dopaminergic re-
ceptor blockade by directly measuring binding affinity (Baumeister & Francis 2002).
The dopamine hypothesis of schizophrenia (DHS) originated in the work of Carlsson and
others on the mechanism of action of antipsychotics, and it has been the best known etiological
theory of modern psychiatry, if not widely accepted, since the late 1970s. As Kenneth Kendler
and Kenneth Schaffner compelling argue, the longevity of the DHS owes much to a conflation
of the scientific evidence for the antipsychotic mechanisms with a theory of schizophrenia since
little solid etiological evidence exists to support the DHS (Kendler & Schaffner 2011). Accord-
ing to Herbert Meltzer and Stephen Stahl in a 1976 American Journal of Psychiatry review of the
hypothesis:
In its simplest form, this hypothesis states that schizophrenia may be related to a relative excess of
DA [dopamine]-dependent neural activity. It is derived from pharmacologic evidence that drugs that
decreaseDA activity (e.g., the phenothiazines) may be antipsychotic and drugs that promoteDA activity
(e.g., amphetamine) may be psychotomimetic. The particular means by which “too much dopamine”
is produced in schizophrenia is not yet known. (Meltzer & Stahl 1976, p. 19)
The DHS has not survived the test of time unscathed. But it exerted a profound influence on sub-
sequent neurobiological research, thus continuing efforts to understand how psychotropic drugs
work, and on the growing belief in the categorical nature of psychiatric disease. In many ways,
Meltzer and Stahl hit upon the fundamental problem in understanding psychiatric disorders by
way of psychopharmacology: the mechanism by which a drug might work, such as by blocking
dopamine, says little about the fundamental nature of the disease, such as “the particular means
by which ‘too much dopamine’ is produced.”Nevertheless, the conflation between mechanisms of
action and theories of psychiatric disease has had a powerful role in the narrowing of psychiatric
vision toward a more exclusively biological perspective.
Similarly, the monoamine hypothesis of depression is based upon the scientific understand-
ing of how antidepressants work. In 1965, two articles appeared, one in the American Journal of
Psychiatry by J.J. Schildkraut (1965) and the other in the Archives of General Psychiatry by William
Bunney and JohnDavis (Bunney &Davis 1965). Both articles propose a catecholamine hypothesis
of depression based upon similar evidence. Schildkraut summarizes the hypothesis as follows:
This hypothesis, which has been designated the “catecholamine hypothesis of affective disorders,”
proposes that some, if not all, depressions are associated with an absolute or relative deficiency of
catecholamines, particularly norepinephrine, at functionally important adrenergic receptor sites in the
brain. (Schildkraut 1965, p. 509)
Similar to the dopamine hypothesis, the catecholamine hypothesis relied upon the effects of drugs,
both clinically and in vitro. Some of the evidence Schildkraut assembles is as follows: MAOI drugs
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increase levels of norepinephrine and serotonin in the brain in animals and are antidepressants
in humans; amphetamine releases norepinephrine from neurons and blocks inactivation; acute
administration of amphetamine causes rebound depression, presumably from depletion of nore-
pinephrine; imipramine, desipramine, and amitriptyline inhibit the reuptake of norepinephrine
into neurons.
Similar to the DHS, the catecholamine hypothesis exerted a profound effect on the ways in
which psychiatric disease was understood and what counted as a legitimate intervention. In par-
ticular, these hypotheses suggest that psychotherapeutic approaches might be of secondary im-
portance in the treatment of psychiatric disease.
4.2. The Randomized Controlled Trial
Although often neglected in the history of psychopharmacology, the RCT was as important in
defining psychiatric illnesses and their treatment as were the psychopharmacological agents them-
selves. Propelled by the 1962 FDA amendment that pharmaceutical companies would have to
prove efficacy as well as safety, the FDA made the RCT the sole arbiter of drug efficacy by the
early 1970s. Not just a rigorous evaluation, the RCT has dramatically altered what counts as a sci-
entific fact for clinical scientists. It dethroned the scientific importance of the individual case study
and, instead, required scientists and clinicians to consider populations of patients, bias,measurable
outcomes, and confounding factors. The RCT shifted the focus from the expertise of the individ-
ual clinician and the unique doctor–patient relationship toward an emphasis on results (most often
quantitative) and interventions that could be replicated across clinicians, patients, space, and time.
The RCT helped to dethrone psychoanalytic dominance and, at the same time, reinforced drug
treatment and associated disease specificity.
The RCT is a relatively new invention. Prior to the mid-twentieth century, clinicians defined
clinical science as expert opinion based upon a mix of historical case–controls, open trials, and
clinical judgement. The origins of the clinical trial have been well documented (Armitage 1972,
Lilienfeld 1982, Kaptchuck 1998). Most locate its formal birth in the United Kingdom’s Medical
Research Council’s streptomycin trials that began in 1946 (Med. Res. Counc. 1948), but the basic
elements that coalesced into this embryonic incarnation of the clinical trial—blinding, controls,
randomization, and placebos—each have their separate histories (Marks 1997). In the 1940s and
1950s, after the introduction of lobotomy and the various shock therapies, psychiatrists began
voicing concerns over the inadequacy of their methods for determining whether a treatment ac-
tually worked (Hoffman 1949, Bourne 1953, Jenkins & Holsopple 1953, Zubin 1953). Nearly all
interventions used prior to the introduction of chlorpromazine failed when scrutinized with the
RCT (Mermelstein 1956, Ackner et al. 1957, Casey et al. 1960).
Lithium, reserpine, and chlorpromazine were the first to be studied using the RCT (Healy
1997, p. 91). In one of the very first randomized trials, Joel and Charmian Elkes (1954) gave chlor-
promazine to 27 patients drawn fromwhat were known as the disturbed wards of the hospital at the
University of Birmingham, United Kingdom, and cautiously concluded: “The reply to the ques-
tion whether the drug may be useful in the management of the chronically overactive psychotic
would thus appear to be qualified ‘yes’” (Elkes & Elkes 1954, p. 564). They gave a more unquali-
fied endorsement of the method they used: “The combination of the ‘blind’ nature of the trial, the
fact that the patient was used as his own control, and agreement among the different observers, all
contributed towards some confidence in a field in which assessment is notoriously difficult” (Elkes
& Elkes 1954, p. 562). Schou et al. (1954) published the first RCT comparing lithiumwith placebo
in patients with mania. Similar to the Elkes’ study, they employed a crossover design. Davies &
Shepherd (1955) from the Maudsley Hospital in London employed the first parallel group design
in their study of reserpine in anxious and depressed patients.
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Yet the RCT was not without its critics, notably psychodynamic psychiatrists, who argued that
the RCT ignored many factors, such as the doctor–patient relationship. In an article aptly titled
“The fallacy of the ‘double blind,’” Joseph Barsa (1963) expressed a commonly held conviction:
It is not possible to gain a valid evaluation of a drug and eliminate the clinical skill and judgement of
the investigator. It is erroneous to believe that treatment with a certain drug will have the same result,
no matter who the therapist is….
Yet, despite all these deficiencies of the ‘double blind’ it is still proposed as the method of choice in the
investigation of psychotropic drugs….However, instead of bringing clarity, the “double blind” has only
succeeded in adding to the confusion by many half-truths and unwarranted conclusions. (Barsa 1963,
p. 1175)
History was not on Barsa’s side. The FDA, under political pressure to define a standard for drug
efficacy that would mediate clinical controversies and override the claims of litigious pharmaceu-
tical companies, enshrined the RCT in 1970 as the single most important arbiter of what counts
as clinical scientific evidence. The well-funded manufacturers responded by perfecting the use of
the RCT as a marketing tool and ensuring its dominance as a standard for therapeutic efficacy.
All scientific methods carry assumptions about the nature of the world; methods shape both
the questions that can be asked and the answers that can be extracted from nature.The RCT lends
itself to a bacteriological model of disease in which illnesses are discrete entities, isolatable from
their sociocultural and psychological context. Because treatment outcomes must be measurable
within RCTs, they are separable from the meanings patients give to the treatment and the doctor–
patient relationship. Thus, the RCT reinforces a reductionist model of psychiatric disease that
mirrors bacteriological perspectives: one in which illnesses are discrete, biological entities without
individual or sociodynamic context.
From the early 1960s to the late 1980s, no new antipsychotic drugs appeared; yet psychophar-
macology helped to radically refashion our understanding of mental illness. While the dramatic
strides in neurobiological understanding helped to affirm the belief that the drugs treated discrete
biological diseases, the RCT helped to crystallize the major disease categories in psychiatry for
which successful treatment requires not only interventions that can be evaluated with RCTs but
also diseases defined by symptoms that the interventions (the drugs) can treat.
In 1964, Jonathan Cole and his colleagues (Cole et al. 1964) published the findings of an impor-
tant multicenter RCT conducted at nine different sites. Funded by theNIMH and one of themost
widely cited in psychiatry and a model for subsequent trials, this study provided definitive proof
of the efficacy of phenothiazine in the treatment of schizophrenia. The researchers randomized
463 patients to four different treatments: chlorpromazine, fluphenazine, thioridazine, or placebo;
they found that patients on phenothiazines did significantly better than those on placebo. The
authors concluded: “The findings of this study support the view that phenothiazine drugs have
a generalized antischizophrenic effect and are useful in patients suffering from acute schizophre-
nia psychoses” (Cole et al. 1964, p. 260), thus reifying the observed effects of the compounds as
definitive of the disease they sought to treat.
4.3. Narrowing Clinical Responsibility
State hospital populations peaked in 1955, coinciding with the widespread introduction of chlor-
promazine and reserpine. At first, many attributed the subsequent fall to the effect of the newly
introduced psychotropic drugs (Brill & Patton 1957, 1959, 1962).Over time, scholars increasingly
questioned the causal relationship between the introduction of antipsychotic drugs and the drop
40 Braslow • Marder
A
nn
u.
 R
ev
. C
lin
. P
sy
ch
ol
. 2
01
9.
15
:2
5-
50
. D
ow
nl
oa
de
d 
fro
m
 w
w
w
.an
nu
al
re
vi
ew
s.o
rg
 
A
cc
es
s p
ro
vi
de
d 
by
 U
ni
ve
rs
ity
 o
f C
al
ifo
rn
ia
 - 
Lo
s A
ng
el
es
 U
CL
A
 o
n 
05
/2
9/
19
. F
or
 p
er
so
na
l u
se
 o
nl
y.
 
CP15CH02_Braslow ARjats.cls April 12, 2019 13:51
in populations in state hospitals (Gronfein 1985, Pow et al. 2015). The historian and sociologist of
psychiatry, Andrew Scull (1990), best summarizes the complex factors that emptied state hospitals:
Themental hospital census, having declined slowly between 1955 and 1965, dropped precipitously over
the next two decades—not primarily, as some have alleged, because phenothiazines provided a tech-
nological fix for the psychosis, but rather in response to a broad expansion of social welfare programs,
growing fiscal pressures on the states, and the opportunity to transfer costs away from the state budget,
helped along, in a more minor key, by the interventions of public interest lawyers who sought to make
it more difficult to employ the police power of the state to compel the mentally ill to enter psychiatric
treatment facilities. (Scull 1990, p. 307)
As the hospitals emptied, psychiatrists became increasingly reliant on psychotropic drugs, no
longer as adjuncts but as the main treatment. Deinstitutionalization led to both increasingly
shorter hospital stays and, up through the 1970s, rising admission rates. As psychiatrists had less
and less time to spend with their patients and had fewer and fewer resources to marshal in their
treatment, they had little choice but to focus on the rapid elimination of symptoms in order to
hasten discharge.
Psychopharmacology’s impressive success also sowed seeds of discontent. Psychotropic drugs
were clearly not curative, even if they dramatically quelled agitated behavior and diminished, but
did not eliminate, the most overt psychotic symptoms. Researchers found it difficult to demon-
strate clinically significant improvement, especially over the long term. Most alarmingly, an-
tipsychotic drugs posed a number of significant side effects. One, in particular, vividly marks its
sufferer. A movement disorder that appears after long-term use of antipsychotic drugs, tardive
dyskinesia entails involuntary movements of the lips, tongue, face, arms or legs, or some combi-
nation of these. It is difficult to reverse, even after the cessation of antipsychotic drugs. By the
1970s, it had become a major concern as researchers discovered that the prevalence was signifi-
cantly higher than had originally been thought (Freeman 1973, Baldessarini et al. 1980, Gelman
1999).
Just as disconcerting was the failure of psychotropic drugs to solve the problems wrought by
deinstitutionalization. Regardless of the impact of antipsychotic drugs in emptying state hospitals,
they did little to solve the problems that those with severe mental illness faced when no longer
able to find solace in the asylum. From the 1970s onward, individuals with severe mental illness
were at increasing risk of homelessness and incarceration as state hospitals contracted in size.
From 1960 to 1969, the population of residents in state hospitals decreased by 31%. During the
next 5 years, the resident population plummeted more than twice as rapidly as it had during the
previous 10 years. In 1974, the resident population was at 215,573, down by 61% from its 1955
high of 558,922 (Kramer 1977). It did not go unnoticed that deinstitutionalization simultaneously
created growing populations of homeless mentally ill people and incarcerated mentally ill people,
facts that underlined that psychotropic drugs were not the hoped-for panacea for those suffering
from severe mental illness.
5. HOPE AND ITS DISCONTENTS: LATE 1980s TO THE PRESENT
The future for psychopharmacology did not look bright in the early 1980s.Despite the publication
of DSM-III, there had been scant clinical progress in psychiatry in regard to psychopharmacology.
No fundamentally new drug had entered the scene for more than two decades, and the enthusiastic
hopes that technological solutions in the guise of psychopharmacology would solve the problems
of severe mental illness had been cruelly dashed by the reality of the collapsing American wel-
fare state and the fragmentation of public services. Yet hope for a pharmacological solution again
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surfaced, although from an unlikely source, in that it came from the rediscovery of a drug that had
first been synthesized in the late 1950s.
5.1. Rediscovery of Clozapine and Atypical Antipsychotic Drugs
In 1958, the Swiss pharmaceutical companyWander had synthesized a series of new tricyclic com-
pounds, including clozapine, the only antipsychotic that produces virtually no tardive dyskinesia
and Parkinson-like side effects.
The early history of clozapine did little to suggest its later major importance (Hippius 1989,
1999, Crilly 2007). Early animal and human testing presented mixed and anomalous results. One
trial failed to demonstrate an antipsychotic effect while another trial succeeded.Later human trials
in the 1960s demonstrated that clozapinewas not only effective in treating psychotic symptoms but
also that it did not produce the motor side effects that invariably accompanied the then-existing
effective antipsychotic drugs. The absence of motor side effects and tardive dyskinesia perplexed
researchers, given the belief that motor side effects were necessary concomitants of drug efficacy.
Clozapine’s defiance of this conventional belief led researchers to designate it as atypical.
When applied in the 1960s, the adjective atypical had a modest, primarily descriptive, meaning
and did little to promote the use of clozapine. In 1975, eight patients in Finland died of agran-
ulocytosis (the inability of the bone marrow to make sufficient white blood cells) while taking
clozapine, which led Sandoz (the pharmaceutical company that had taken over Wander) to halt
development efforts. Nevertheless, increasing concerns over tardive dyskinesia, and a suspicion
that clozapine might be more effective than other antipsychotic drugs, kept a few embers of inter-
est in the drug alive. Beginning in 1984, Sandoz conducted a multicenter study that demonstrated
the superior efficacy of clozapine over chlorpromazine in patients previously unresponsive to an-
tipsychotic drugs (Kane et al. 1988, 1989). Sandoz also instituted a system of mandatory blood
monitoring in patients taking clozapine so that the medication could be stopped if white blood
cell counts began to drop, thereby preventing the onset of agranulocytosis. In 1990, the FDA gave
final approval for the exclusive marketing of clozapine.
Not unlike the 1964 US NIMH study led by Cole, this study had profound effects on the field
of psychopharmacology in general and the treatment of psychotic disorders in particular. It af-
firmed the growing skepticism that dopamine blockade (especially of the D2 receptors) was a nec-
essary ingredient for antipsychotic efficacy in light of the continued failures to identify dopamine
abnormalities postmortem in patients with schizophrenia. The fact that clozapine did not ap-
preciably block D2 receptors and had no motor side effects further imperiled the dopamine hy-
pothesis and, from the 1970s onward, led pharmaceutical companies to use clozapine, with its
higher affinity for serotonergic rather than dopaminergic receptors, as a new model for drug
development.
Such reasoning led Janssen Pharmaceuticals to the synthesis of risperidone in 1984. The com-
pany obtained FDA approval in 1993 to market it as Risperdal. Janssen enthusiastically embraced
the term atypical, and risperidone become the first new atypical antipsychotic drug marketed in
the United States. In 1996, Eli Lilly brought to market the atypical antipsychotic drug olanzap-
ine (brand name Zyprexa). A year later, the FDA approved AstraZeneca’s quetiapine (brand name
Seroquel). Eight additional atypical antipsychotic drugs have entered the US market since 2000,
including such widely prescribed compounds as aripiprazole in 2002 (trade name Abilify; Otsuka
Pharmaceutical and Bristol-Myers Squibb), paliperidone in 2006 (trade name Invega; Janssen),
and lurasidone in 2010 (brand name Latuda; Sumitomo Dainippon Pharma).
Throughout much of the 1990s and early 2000s, these drugs were hailed as major advances,
fundamentally better than the first generation of antipsychotic drugs. Certainly, classification of
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these new drugs as atypical helped, distancing them from the drugs developed in the 1950s and
1960s and the widespread disappointment that clung to them as long-term outcomes failed to
improve (Insel 2010) and side effects increased. Also, neuroreceptor mythology, related to the ac-
tivity of risperidone and others at 5-HT2A receptors, helped to reinforce the hope, if not the belief,
that they were a fundamental advance. Some of the new drugs do, in fact, have great relative affin-
ity for 5-HT2A receptors, although this is not universally characteristic of all second-generation
agents. Pharmaceutical companies heavily promoted atypicals as more effective and safer than
the first generation of antipsychotic drugs, especially for social withdrawal and cognitive deficits,
core symptoms of schizophrenia that were untouched by first-generation antipsychotic drugs.The
claims of safety did not hold up to scrutiny (see Section 5.4) as severe metabolic disturbances be-
came apparent. It is likely (although not certain) that atypicals cause fewer movement disorders
than do the first-generation drugs. Clozapine, however, remains the only antipsychotic that is
virtually free from these side effects.
5.2. Better than Well: The Rise of the SSRIs
At the same time as the pharmaceutical industry looked toward developing novel antipsychotic
drugs, they also turned their attention toward developing new antidepressants. Serotonin and its
role in mental illness had been of interest ever since the 1950s. In 1954, John Gaddum, after acci-
dentally ingesting LSD,which was already known to block serotonin, discovered that it had strong
psychotropic effects, describing being “out of his mind for forty-eight hours” (Shorter 2008, p. 69).
Then, in 1957, Bernard Brodie demonstrated that reserpine depleted neuronal stores when given
to rabbits, which appeared to behave in a depressed manner, consistent with previous reports that
some human patients became severely depressed when taking reserpine (Brodie & Shore 1957).
However, interest in the role of serotonin was eclipsed after 1961 by Julius Axelrod et al.’s (1961)
discovery that imipramine inhibited the reuptake of norepinephrine but not serotonin in neurons.
Yet some researchers maintained an interest in serotonin and its possible role in depressive states,
and in 1974, researchers at Eli Lilly developed a molecule that selectively blocked the reuptake of
serotonin (Hillhouse & Porter 2015). This molecule was named fluoxetine, and Eli Lilly received
FDA approval in 1987 to market it as an antidepressant under the trade name Prozac. Prozac was
launched in 1988.
Other SSRIs quickly followed: sertraline (trade name Zoloft; Pfizer) in 1991, paroxetine (trade
name Paxil; GlaxoSmithKline) in 1992, and citalopram (trade name Celexa; Allergan) in 1998. In
contrast to older drugs for depression, fluoxetine was relatively easy to administer because of its
side effect profile. As a result, patients with milder depressions appeared to benefit, and treatment
could often be managed in primary care settings. Because of the apparent ease of prescription, the
companies heavily marketed these drugs to primary care clinicians and consumers. Although un-
supported by anything more substantial than clinical anecdote, Prozac achieved an almost mythic
status as capable of making one even better than well. Emblematic of the hype that surrounded
Prozac, Peter Kramer’s Listening to Prozac claimed that Prozac possesses the ability to fundamen-
tally remake personality and, as such, raises fundamental questions about the nature of the self
(Kramer 1994). Irrespective of the thin evidence upon which such assertions rested, Listening to
Prozac and the hubbub surrounding the first major psychotropic blockbuster since Valium gener-
ated a deep popular belief that the SSRIs represented a fundamental advance.
5.3. Pharmaceutical Profits and Psychotropic Drugs
Both the atypical antipsychotics and SSRI antidepressants produced spectacular profits for the
pharmaceutical industry. The industry revived a moribund sector that had not marketed a
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fundamentally new drug for more than two decades and, in a matter of just a few years, not only
completely conquered the existing markets for antipsychotic and antidepressant drugs but also
forged new ones. In the case of atypicals, although they were initially approved only for the treat-
ment of schizophrenia, off-label use grew rapidly as the illusion of safety and efficacy encouraged
physicians to prescribe atypicals for a variety of psychological ills, ranging from insomnia, anxiety,
depression, and dementia to a host of childhood disorders. By the early 2000s, patients with bipolar
disorder, depression, and dementia overtook patients with schizophrenia as the largest market for
atypicals (Olfson et al. 2015). In expanding market share at the expense of the first generation, the
pharmaceutical industry heavily marketed these agents as not only being safer and having fewer
motor side effects but also as being more efficacious.
The launch of Risperdal in 1993 inaugurated a transformation of the market for antipsychotic
drugs that produced previously unimaginable profits. On the eve of Risperdal’s introduction,
worldwide sales of antipsychotic drugs amounted to less than a billion dollars, with clozapine,
the only marketed atypical, accounting for only a small fraction of this sum. During the next
decade, atypical antipsychotic drugs captured more than 90% of the market, and worldwide sales
of these compounds mushroomed to more than $10 billion. By 2011, sales of antipsychotic drugs
topped $28 billion, becoming the fifth largest–selling drug class, just behind oncologics, respi-
ratory agents, antidiabetics, and lipid regulators. The US pharmaceutical market accounted for
the majority of these expenditures (as it does for the majority of pharmaceutical classes). Of the
$28 billion spent on antipsychotic drugs in 2011, expenditures in the United States accounted for
64% of the total or $18.2 billion (https://www.iqvia.com/).
Companies were similarly successful in selling SSRIs. They handily conquered market share
over the tricyclics and expanded into entirely new populations, including people diagnosed with
obsessive–compulsive disorder, panic disorder, generalized anxiety disorder, social anxiety disor-
der, posttraumatic stress disorder, and premenstrual dysphoric disorder. In addition, the perceived
safety of these compounds led to an increase in the use of antidepressants in children and ado-
lescents. Prior to the introduction of fluoxetine in 1988, 40 million Americans were treated with
an antidepressant, whereas 264 million received an antidepressant in 2011. A national survey con-
ducted from 2009 to 2010 found that 10.4% of adults were taking an antidepressant. Moreover,
these medications were most commonly being prescribed by primary care providers (Mojtabai &
Olfson 2014).
5.4. A Darker Side
Just as the profits of SSRIs soared, a number of major problems emerged. Researchers began
questioning the efficacy of SSRIs (Kirsch 2010,Wang et al. 2018). In 2003, the FDA issued an ad-
visory that there was an increased risk for suicide in pediatric patients prescribed antidepressants.
This was followed by warnings that both adults and children prescribed antidepressants should be
monitored for suicidal behavior. In 2004, the FDA required a black box warning for all antidepres-
sants stating that there was increased risk of suicidality in children, adolescents, and young adults.
Before the FDA advisory, the rates of pediatric depression had been steadily rising. Following
the advisory, there was both a decline in the diagnosis of depression in children, adolescents, and
young adults and a decrease in the prescribing of antidepressants for these groups (Libby et al.
2007). Although the FDA advisory focused on children and adolescents, there was also a decline
in the diagnosis of depression in adults (Valuck et al. 2007).
The atypical antipsychotic drugs encountered similar difficulties. The enthusiastic appraisals
that the atypicals were more efficacious than the first generation did not hold up to close scrutiny.
Clozapine remains the only atypical antipsychotic drug with proven superior efficacy over the
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older drugs. Published in 2005 and 2006, two studies have proven to be especially influen-
tial demonstrations that atypicals, as a class, offer few advantages over the older drugs. One
study, funded by the NIMH, compared a number of second-generation antipsychotics with per-
phenazine, an older drug (Lieberman et al. 2005). Although side effects differed among the drugs,
there was no clear indication that perphenazine was less effective than the newer drugs. A 2006
study compared atypical with first-generation antipsychotic drugs in 14 sites across the United
Kingdom.The researchers concluded that “there is no disadvantage across 1 year in terms of qual-
ity of life, symptoms, or associated costs of care” in using the first-generation antipsychotics com-
pared with the non-clozapine atypicals ( Jones et al. 2006, p. 1086). More recently, meta-analyses
comparing antipsychotics have not found an efficacy advantage for newer drugs (Leucht et al.
2013).
None of the new drugs has been able to mimic clozapine’s virtual absence of extrapyramidal
side effects and tardive dyskinesia. They all produce some degree of motor side effects, although
perhaps less often than first-generation drugs. At the same time, these newer drugs produce a va-
riety of metabolic side effects that are as serious, if not more so, than those that plagued the first
generation of antipsychotics. Significant weight gain, diabetes, and hyperlipidemia (elevated levels
of lipids in the bloodstream associated with heightened risk of cardiovascular disease) are common
side effects, although each of the newer antipsychotic drugs varies in the extent to which it pro-
duces these side effects. Nevertheless, these effects are not a defining characteristic of the newer
antipsychotics. These effects had been noted in patients treated with clozapine as well as with
first-generation antipsychotics. Antipsychotics such as ziprasidone and lurasidone have relatively
small risks for these effects.
A darker side of pharmaceutical industry practices has been laid bare in a number of landmark
lawsuits regarding the atypicals. Eli Lilly, Pfizer, AstraZeneca, Bristol-Myers Squibb, and Johnson
& Johnson have been charged with or investigated for health-care fraud. In 2007, Bristol-Myers
Squibb paid $515 million to settle allegations that the company had promoted Abilify (aripipra-
zole) for use in children and to treat dementia. In 2009, Eli Lilly paid $1.4 billion to settle al-
legations that it marketed Zyprexa (olanzapine) for a variety of unapproved uses. In the same
year, Pfizer settled a major suit for the illegal marketing of Geodon (ziprasidone), and in 2010,
AstraZeneca paid $520 million for the illegal marketing of Seroquel (quetiapine).
In retrospect, atypicality has served asmuch as amarketing tool as it has a legitimate description
of a differently acting class of antipsychotic drugs.The term atypical increasingly has lost its mean-
ing as we learn more about the efficacy and side effects of these drugs. After all, other than cloza-
pine, all antipsychotic drugs (new and old) have nearly equivalent efficacy; all produce nasty side
effects, some potentially fatal; and none works nearly as well as clinicians and patients wish it did.
Finally, a worrisome trend that bodes ill for future drug development is that a number of large
companies recently either have closed their divisions for neuroscience drug development or sub-
stantially limited their investment in it. The industry has based this retreat on an expectation that
development costs will not be offset by future profits. Ironically, fueled by the antipsychotic and
antidepressant drug markets, the pharmaceutical industry has reaped enormous profits from psy-
chotropic drugs. For example, between 1997 and 2001, US sales of psychotropic drugs increased
by 24% per year (Mark et al. 2012). When considering total expenditures for mental health care,
this growth comes at a cost in that expenditures for other components of care have not increased
proportionally.During the same period, the amount of the total expenditure onmental health care
increased from 14% to 23%. In 2012, the total amount spent in the United States on psychotropic
drugs was $57.8 billion (of which, antidepressants accounted for $17.8 billion and antipsychotics
accounted for $17.6 billion). Psychotropic drugs made up 21% of the total spent on all pharma-
ceuticals (Hodgkin et al. 2016).
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However, the rate of growth for psychotropic drugs has declined steadily since 2001—largely
due to market saturation, declining drug prices, and loss of patent protection—with the associ-
ated influx of generics. While not necessarily in the public interest, the decision to shift research
and development resources to other diseases likely makes business sense. Looking back, the drugs
introduced since Prozac have reaped unimaginably huge profits despite being only marginally bet-
ter than the drugs they have replaced. Perhaps pharmaceutical executives have made a calculated
gamble that lightning usually does not strike twice.
6. CONCLUSIONS
Stepping back, the history of psychopharmacology and, indeed, the entire history of psychiatry
look a bit like Sisyphus repeatedly pushing an enormous boulder up a hill only to have it come
crashing back down just as it nears the crest. Psychiatrists keep believing that they are on the
verge of radical breakthroughs in the care and treatment of mental illness only to have their hopes
dashed by the reality of the enormous complexities of interactions between human psychologi-
cal life, the brain, and the social world. Psychiatry and American culture have been particularly
seduced by the technological solutions promised by a magic bullet that will simultaneously cure
madness and provide simple explanations for the inexplicable. Psychopharmacological solutions
have been especially compelling during the past 50 years since they require far fewer questions of
how America cares for those unable to care for themselves.
One might despair. But we believe that this history is actually a hopeful one if we take seriously
the lessons it has to teach us about the nature of mental illness. It is not that psychopharmacology
has failed. Instead, we have failed our patients by adopting a myopia that sees only symptoms and
their alleviation by psychoactive drugs. This narrowing of vision has been aided and abetted by a
fraying social safety net and fragmented health-care system in which drugs increasingly are all psy-
chiatrists feel they can offer their patients. But the failures of antipsychotic drugs, for example, to
miraculously solve the consequences of deinstitutionalization teach us the enormously important
lesson that mental illness, by definition, is a disease of the biological, psychological, and social.
During the past several decades, there has been a concerted effort in the care of patients with
severe mental illness to instill hope that they are not fated to a life of disability. For our patients,
we do not believe that biology is destiny. The history of psychopharmacology reminds us of that
fact. While helpful, psychotropic drugs cannot and will not (at least for the foreseeable future)
by themselves adequately treat the ravages of mental illness. Although we do not advocate a re-
turn to the past, we do believe that we have much to learn from that innocent world before the
psychopharmacological era during which there was more to patients than simply symptoms and
drugs taken to treat those symptoms.
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